Charles Duncan's Stock Ratings

Cantor Fitzgerald Analyst

Charles Duncan is an analyst at Cantor Fitzgerald. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/16/2024

Overall Average Return

14.8%

Smart Score

67.1%

Overall Average Return Percentile

70th

Number of Ratings

154
Buy NowGet Alert
05/09/2024ACADBuy Now
ACADIA Pharmaceuticals
$14.85149.16% → $37ReiteratesOverweight → OverweightGet Alert
04/30/2024ACADBuy Now
ACADIA Pharmaceuticals
$14.85149.16% → $37ReiteratesOverweight → OverweightGet Alert
04/30/2024CMPSBuy Now
Compass Pathways
$8.38——Reiterates → OverweightGet Alert
04/24/2024ITCIBuy Now
Intra-Cellular Therapies
$66.5380.37% → $120ReiteratesOverweight → OverweightGet Alert
04/19/2024CMPSBuy Now
Compass Pathways
$8.38——Reiterates → OverweightGet Alert
04/18/2024CMPSBuy Now
Compass Pathways
$8.38——Reiterates → OverweightGet Alert
04/18/2024BHVNBuy Now
Biohaven
$38.75——Reiterates → OverweightGet Alert
04/12/2024HRMYBuy Now
Harmony Biosciences
$29.3167.18% → $49ReiteratesOverweight → OverweightGet Alert
04/10/2024BHVNBuy Now
Biohaven
$38.75——Reiterates → OverweightGet Alert
04/10/2024PRTABuy Now
Prothena Corp
$23.39——Reiterates → OverweightGet Alert
04/10/2024NBIXBuy Now
Neurocrine Biosciences
$141.919.22% → $155ReiteratesOverweight → OverweightGet Alert
04/10/2024MRNSBuy Now
Marinus Pharma
$1.341989.55% → $28ReiteratesOverweight → OverweightGet Alert
04/10/2024JAZZBuy Now
Jazz Pharmaceuticals
$110.4962.91% → $180ReiteratesOverweight → OverweightGet Alert
04/10/2024AXSMBuy Now
Axsome Therapeutics
$77.0038.96% → $107ReiteratesOverweight → OverweightGet Alert
04/10/2024ACADBuy Now
ACADIA Pharmaceuticals
$14.85149.16% → $37ReiteratesOverweight → OverweightGet Alert
04/04/2024ATAIBuy Now
ATAI Life Sciences
$1.97——Reiterates → OverweightGet Alert
04/04/2024STOKBuy Now
Stoke Therapeutics
$14.15——Reiterates → OverweightGet Alert
03/28/2024HRMYBuy Now
Harmony Biosciences
$29.3167.18% → $49ReiteratesOverweight → OverweightGet Alert
03/22/2024CPRXBuy Now
Catalyst Pharmaceuticals
$16.49106.19% → $34ReiteratesOverweight → OverweightGet Alert
03/22/2024JAZZBuy Now
Jazz Pharmaceuticals
$110.4962.91% → $180ReiteratesOverweight → OverweightGet Alert
03/14/2024CPRXBuy Now
Catalyst Pharmaceuticals
$16.49106.19% → $34ReiteratesOverweight → OverweightGet Alert
03/12/2024ACADBuy Now
ACADIA Pharmaceuticals
$14.85149.16%$42 → $37MaintainsOverweightGet Alert
03/01/2024CPRXBuy Now
Catalyst Pharmaceuticals
$16.49106.19%$27 → $34MaintainsOverweightGet Alert
02/29/2024JAZZBuy Now
Jazz Pharmaceuticals
$110.4962.91% → $180ReiteratesOverweight → OverweightGet Alert
02/28/2024ACADBuy Now
ACADIA Pharmaceuticals
$14.85182.83% → $42ReiteratesOverweight → OverweightGet Alert
02/23/2024HRMYBuy Now
Harmony Biosciences
$29.3167.18% → $49ReiteratesOverweight → OverweightGet Alert
02/23/2024ITCIBuy Now
Intra-Cellular Therapies
$66.5351.81% → $101ReiteratesOverweight → OverweightGet Alert
02/21/2024AXSMBuy Now
Axsome Therapeutics
$77.0033.77%$108 → $103MaintainsOverweightGet Alert
02/20/2024KRTXBuy Now
Karuna Therapeutics
—— → $330ReiteratesNeutral → NeutralGet Alert
02/20/2024AXSMBuy Now
Axsome Therapeutics
$77.0040.26% → $108ReiteratesOverweight → OverweightGet Alert